BIO-KEY INTERNATIONAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.58 USD | +5.33% |
|
-7.33% | -47.33% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 10.48 | 7.204 | 27.46 | 17.31 | 5.363 | 2.86 | 2.86 |
| Enterprise Value (EV) 1 | 10.48 | 8.868 | 10.69 | 9.559 | 4.751 | 1.96 | 0.5605 |
| P/E ratio | -1.03 x | - | - | - | - | - | - |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.59 x | 3.18 x | 9.68 x | 3.39 x | 0.76 x | 0.32 x | 0.19 x |
| EV / Revenue | 2.59 x | 3.91 x | 3.77 x | 1.87 x | 0.68 x | 0.22 x | 0.04 x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | - | -4,719,207 x | -2,143,342 x | - | - | - | - |
| FCF Yield | - | -0% | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 97.1 | 100 | 433 | 435 | 509 | 1,810 | 1,810 |
| Reference price 2 | 108.0 | 72.00 | 63.36 | 39.78 | 10.53 | 1.580 | 1.580 |
| Announcement Date | 4/1/19 | 5/14/20 | 3/25/21 | 3/29/22 | 3/31/23 | - | - |
1USD in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.045 | 2.268 | 2.837 | 5.114 | 7.02 | 9 | 15 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -6.869 | -6.562 | -4.411 | -4.627 | -7.6 | -2.6 | 1.85 |
| Operating Margin | -169.83% | -289.4% | -155.5% | -90.47% | -108.25% | -28.89% | 12.33% |
| Earnings before Tax (EBT) | -6.869 | - | - | - | - | - | - |
| Net income 1 | -8.496 | -14.59 | -9.787 | -5.066 | -10.23 | -3.2 | 1 |
| Net margin | -210.06% | -643.37% | -344.99% | -99.05% | -145.74% | -35.56% | 6.67% |
| EPS | -105.1 | - | - | - | - | - | - |
| Free Cash Flow | - | -1.879 | -4.986 | - | - | - | - |
| FCF margin | - | -82.87% | -175.75% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/1/19 | 5/14/20 | 3/25/21 | 3/29/22 | 3/31/23 | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.9921 | 1.299 | 0.9349 | 1.941 | 1.947 | 1.374 | 1.758 | 3.084 | 1.929 | 1.828 | 2.17 | 3.7 | 3.1 | 2.8 | 5.5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.071 | -0.9359 | -1.925 | -0.9995 | -1.484 | -2.26 | -2.974 | -0.3084 | -1.179 | -0.7493 | -0.7 | 0.5 | - | -0.2 | 1.5 |
| Operating Margin | -107.99% | -72.06% | -205.89% | -51.49% | -76.2% | -164.52% | -169.12% | -10% | -61.1% | -40.98% | -32.26% | 13.51% | - | -7.14% | 27.27% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | -1.162 | -1.024 | -2.029 | -0.9994 | -1.719 | -2.522 | -5.111 | -0.5265 | - | -0.7491 | -0.8 | - | - | - | - |
| Net margin | -117.09% | -78.81% | -217.02% | -51.48% | -88.28% | -183.6% | -290.63% | -17.07% | - | -40.97% | -36.87% | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/16/21 | 11/15/21 | 3/29/22 | 5/16/22 | 8/12/22 | 11/14/22 | 3/31/23 | 5/16/23 | 8/14/23 | 10/25/23 | - | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1.66 | - | - | - | - | - |
| Net Cash position 1 | - | - | 16.8 | 7.75 | 0.61 | 0.9 | 2.3 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -1.88 | -4.99 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | 0.05 | 0.03 | 0.04 | - | - | - | - |
| Capex / Sales | 1.29% | 1.27% | 1.25% | - | - | - | - |
| Announcement Date | 4/1/19 | 5/14/20 | 3/25/21 | 3/29/22 | 3/31/23 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.58
USD
Average target price
18
USD
Spread / Average Target
+1,039.24%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -47.33% | 2.86M | |
| -25.52% | 1.55B | |
| +186.73% | 161M | |
| +14.63% | 120M | |
| -44.01% | 53.47M |
- Stock Market
- Equities
- BKYI Stock
- Financials BIO-key International, Inc.
